Phaseline

Companies › Zenith Epigenetics

Zenith Epigenetics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ZEN003694
HDAC inhibitor
–Phase 2Metastatic Castration-Resistant Prostate Cancer; Squamous Cell Lung Cancer; Ovarian CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04986423ZEN003694Phase 2Metastatic Castration-Resistant Prostate CancerOncologyDec 2026
NCT05607108ZEN003694Phase 2Squamous Cell Lung CancerOncologyNov 2027
NCT05071937ZEN003694Phase 2Ovarian CancerOncologyNov 2033

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.